This webinar discusses development and validation of an assay for detection of microsatellite instability (MSI) based on a novel set of biomarkers.

Detection of MSI is currently recommended for all patients with colorectal cancer (CRC), but MSI is present in several other tumor types such as ovarian and gastric cancer. Current clinical reference methods are immunohistochemical staining of mismatch repair proteins and/or PCR analysis of frequently mutated short tandem repeat regions of DNA, but these approaches are complex and time-consuming.

In this webinar, Bram De Craene of Biocartis discusses the development and performance of the company's Idylla MSI Assay and compares the technology with established methods. He shares details of how the company assessed the suitability and robustness of the novel marker set to detect MSI status in CRC, and discusses the role of the Horizon’s MSI and MSS reference material in evaluating the analytical performance of the assay.

The Idylla MSI Assay is available for research use only. Not for use in diagnostic procedures.